{"title_page": "Spartalizumab", "text_new": "{{Infobox drug\n| type              = mab\n| image             = \n| alt               = \n| mab_type          = mab\n| source            = zu\n| target            = [[programmed cell death 1|PDCD1]], [[CD279]]\n| pronounce         =\n| tradename         = \n| Drugs.com         = \n| MedlinePlus       = \n| pregnancy_AU      = \n| pregnancy_US      = \n| pregnancy_category=  \n| legal_AU = \n| legal_AU_comment =\n| legal_BR =  \n| legal_BR_comment =\n| legal_CA = \n| legal_UK = \n| legal_US = \n| legal_UN = \n| legal_NZ = \n| legal_status      = \n| routes_of_administration = \n| bioavailability   = \n| protein_bound     = \n| metabolism        = \n| metabolites       =\n| onset             = \n| elimination_half-life = \n| duration_of_action=\n| excretion         =\n| CAS_number        = 1935694-88-4\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = QOG25L6Z8Z\n| ATC_prefix        = none\n| ATC_suffix        = \n| PubChem           = \n| DrugBank          = \n| KEGG          = D11605\n| C = | H = | N = | O = | S = \n| molecular_weight  = \n| UNII = \n| synonyms = PDR001\n}}\n\n'''Spartalizumab''' ([[International Nonproprietary Name|INN]];<ref name=WHOList117>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117 | journal = WHO Drug Information | volume = 31 | issue = 2 | year = 2017 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL117.pdf | format=PDF}}</ref> development code '''PDR001''') is a monoclonal antibody that is being investigated for [[melanoma]].\n\nThis drug is being developed by [[Novartis]]. {{as of|2018}}, spartalizumab is undergoing [[Phase III]] trials.\n\n== References ==\n<references/>\n{{monoclonal-antibody-stub}}\n{{monoclonals for immune system}}\n[[Category:Monoclonal antibodies]]\n", "text_old": "{{Infobox drug\n| type              = mab\n| image             = \n| alt               = \n| mab_type          = mab\n| source            = zu\n| target            = [[programmed cell death 1|PDCD1]], [[CD279]]\n| pronounce         =\n| tradename         = \n| Drugs.com         = \n| MedlinePlus       = \n| pregnancy_AU      = \n| pregnancy_US      = \n| pregnancy_category=  \n| legal_AU = \n| legal_AU_comment =\n| legal_BR =  \n| legal_BR_comment =\n| legal_CA = \n| legal_UK = \n| legal_US = \n| legal_UN = \n| legal_NZ = \n| legal_status      = \n| routes_of_administration = \n| bioavailability   = \n| protein_bound     = \n| metabolism        = \n| metabolites       =\n| onset             = \n| elimination_half-life = \n| duration_of_action=\n| excretion         =\n| CAS_number        = 1935694-88-4\n| ATC_prefix        = none\n| ATC_suffix        = \n| PubChem           = \n| DrugBank          = \n| KEGG          = D11605\n| C = | H = | N = | O = | S = \n| molecular_weight  = \n| UNII = \n| synonyms = PDR001\n}}\n\n'''Spartalizumab''' ([[International Nonproprietary Name|INN]];<ref name=WHOList117>{{cite journal | author = [[World Health Organization]] | title = International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117 | journal = WHO Drug Information | volume = 31 | issue = 2 | year = 2017 | url = http://www.who.int/medicines/publications/druginformation/innlists/PL117.pdf | format=PDF}}</ref> development code '''PDR001''') is a monoclonal antibody that is being investigated for [[melanoma]].\n\nThis drug is being developed by [[Novartis]]. {{as of|2018}}, spartalizumab is undergoing [[Phase III]] trials.\n\n== References ==\n<references/>\n{{monoclonal-antibody-stub}}\n{{monoclonals for immune system}}\n[[Category:Monoclonal antibodies]]\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/Spartalizumab"}
